Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Nicotinic acid 500 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Albendazole 200 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
abakavir 300 milligram, lamivudin 150 milligram och zidovudin 300 milligram, oral tablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
abakavir 300 milligram, lamivudin 150 milligram och zidovudin 300 milligram, oral tablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
abakavir 300 milligram, lamivudin 150 milligram och zidovudin 300 milligram, oral tablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
3 |
Aspirin 325 mg and butalbital 50 mg and caffeine 40 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Aspirin 325 mg and butalbital 50 mg and caffeine 40 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Aspirin 325 mg and butalbital 50 mg and caffeine 40 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
3 |
Aspirin 385 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Aspirin 385 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Aspirin 385 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
3 |
Aspirin 428 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Aspirin 428 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Aspirin 428 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
3 |
Aspirin 770 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Aspirin 770 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Aspirin 770 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
3 |
Aspirin 856 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Aspirin 856 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Aspirin 856 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
3 |
Aspirin 325 mg and carisoprodol 200 mg and codeine phosphate 16 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Aspirin 325 mg and carisoprodol 200 mg and codeine phosphate 16 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Aspirin 325 mg and carisoprodol 200 mg and codeine phosphate 16 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
3 |
Aspirin 325 mg and carisoprodol 200 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Aspirin 325 mg and carisoprodol 200 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Aspirin 500 mg and hydrocodone bitartrate 5 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Aspirin 500 mg and hydrocodone bitartrate 5 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Aspirin 325 mg and meprobamate 200 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Aspirin 325 mg and meprobamate 200 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Aspirin 325 mg and methocarbamol 400 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Aspirin 325 mg and methocarbamol 400 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Product containing precisely aspirin 325 milligram and oxycodone hydrochloride 2.25 milligram and oxycodone terephthalate 190 microgram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely aspirin 325 milligram and oxycodone hydrochloride 2.25 milligram and oxycodone terephthalate 190 microgram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Product containing precisely aspirin 325 milligram and oxycodone hydrochloride 2.25 milligram and oxycodone terephthalate 190 microgram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
3 |
Aspirin 325 mg and oxycodone hydrochloride 4.5 mg and oxycodone terephthalate 380 microgram oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Aspirin 325 mg and oxycodone hydrochloride 4.5 mg and oxycodone terephthalate 380 microgram oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Aspirin 325 mg and oxycodone hydrochloride 4.5 mg and oxycodone terephthalate 380 microgram oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
3 |
Atenolol 100 mg and chlortalidone 25 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Atenolol 100 mg and chlortalidone 25 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Atenolol 50 mg and chlortalidone 25 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Atenolol 50 mg and chlortalidone 25 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
atovakvon 62,5 mg + proguanilhydroklorid 25 mg, tablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
atovakvon 62,5 mg + proguanilhydroklorid 25 mg, tablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
atropin 25 mikrogram och difenoxinhydroklorid 1 milligram, oral tablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
atropin 25 mikrogram och difenoxinhydroklorid 1 milligram, oral tablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Atropine sulfate 25 microgram and diphenoxylate hydrochloride 2.5 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Atropine sulfate 25 microgram and diphenoxylate hydrochloride 2.5 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Product containing precisely atropine sulfate 19.4 microgram and hyoscyamine sulfate 103.7 microgram and scopolamine hydrobromide 6.5 microgram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely atropine sulfate 19.4 microgram and hyoscyamine sulfate 103.7 microgram and scopolamine hydrobromide 6.5 microgram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Product containing precisely atropine sulfate 19.4 microgram and hyoscyamine sulfate 103.7 microgram and scopolamine hydrobromide 6.5 microgram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
3 |
Azatadine maleate 1 mg and pseudoephedrine sulfate 120 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Azatadine maleate 1 mg and pseudoephedrine sulfate 120 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Product containing precisely belladonna alkaloid 200 microgram and ergotamine tartrate 600 microgram and phenobarbital 40 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely belladonna alkaloid 200 microgram and ergotamine tartrate 600 microgram and phenobarbital 40 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Product containing precisely belladonna alkaloid 200 microgram and ergotamine tartrate 600 microgram and phenobarbital 40 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
3 |
Benazepril hydrochloride 10 mg and hydrochlorothiazide 12.5 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Benazepril hydrochloride 10 mg and hydrochlorothiazide 12.5 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
bisoprolol 5 milligram och hydroklortiazid 6,25 milligram, oral tablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
bisoprolol 5 milligram och hydroklortiazid 6,25 milligram, oral tablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Candesartan cilexetil 16 mg and hydrochlorothiazide 12.5 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Candesartan cilexetil 16 mg and hydrochlorothiazide 12.5 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Captopril 25 mg and hydrochlorothiazide 15 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Captopril 25 mg and hydrochlorothiazide 15 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Captopril 25 mg and hydrochlorothiazide 25 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Captopril 25 mg and hydrochlorothiazide 25 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Captopril 50 mg and hydrochlorothiazide 15 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Captopril 50 mg and hydrochlorothiazide 15 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
karbidopa 10 mg + levodopa 100 mg, tablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
karbidopa 10 mg + levodopa 100 mg, tablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
karbidopa 25 mg + levodopa 100 mg, tablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
karbidopa 25 mg + levodopa 100 mg, tablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
karbidopa 25 mg + levodopa 250 mg, tablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
karbidopa 25 mg + levodopa 250 mg, tablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Chlorothiazide 250 mg and methyldopa 250 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Chlorothiazide 250 mg and methyldopa 250 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Chlorothiazide 250 mg and reserpine 125 microgram oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Chlorothiazide 250 mg and reserpine 125 microgram oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Product containing precisely chlorothiazide 500 milligram and reserpine 125 microgram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely chlorothiazide 500 milligram and reserpine 125 microgram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Homatropine methylbromide 1.5 mg and hydrocodone bitartrate 5 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Homatropine methylbromide 1.5 mg and hydrocodone bitartrate 5 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Hydralazine hydrochloride 25 mg and hydrochlorothiazide 15 mg and reserpine 100 microgram oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Hydralazine hydrochloride 25 mg and hydrochlorothiazide 15 mg and reserpine 100 microgram oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Hydralazine hydrochloride 25 mg and hydrochlorothiazide 15 mg and reserpine 100 microgram oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
3 |
Product containing precisely methenamine mandelate 500 milligram and monobasic sodium phosphate 500 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely methenamine mandelate 500 milligram and monobasic sodium phosphate 500 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Methscopolamine 2.5 mg and pseudoephedrine hydrochloride 120 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Methscopolamine 2.5 mg and pseudoephedrine hydrochloride 120 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Methyclothiazide 2.5 mg and reserpine 100 microgram oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Methyclothiazide 2.5 mg and reserpine 100 microgram oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Product containing precisely naloxone hydrochloride 500 microgram and pentazocine hydrochloride 50 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely naloxone hydrochloride 500 microgram and pentazocine hydrochloride 50 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Amiloride hydrochloride 5 mg and hydrochlorothiazide 50 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Amiloride hydrochloride 5 mg and hydrochlorothiazide 50 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
amitriptylinhydroklorid 12,5 milligram och klordiazepoxid 5 milligram, oral tablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
amitriptylinhydroklorid 12,5 milligram och klordiazepoxid 5 milligram, oral tablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
amitriptylin 10 milligram och perfenazin 4 milligram, oral tablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
amitriptylin 10 milligram och perfenazin 4 milligram, oral tablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Olmesartan medoxomil 5 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Olmesartan medoxomil 20 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Olmesartan medoxomil 40 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |